Researchers have reported encouraging results from a clinical trial exploring a potential antiviral treatment for Long Covid, according to a University of Exeter news release. The £1.2 million study, known as the ERASE trial, was led by the University of Derby in collaboration with the University of Exeter and managed by the University of Plymouth's Peninsula Clinical Trials Unit.
The trial, which began in September 2024, tested whether an antiviral drug delivered intravenously over five consecutive days could be used to treat people with Long Covid. The study involved 73 patients who underwent assessments at specialist facilities at the University of Derby and the University of Exeter before receiving the treatment from clinical teams at University Hospitals of Derby and Burton NHS Foundation Trust and the NIHR Exeter Clinical Research facility at the Royal Devon University Healthcare NHS Foundation Trust, in partnership with Aston University.
The researchers found that the five-day intravenous treatment regimen could be successfully delivered and that participants were able to complete the clinical assessments required for the research. The study also generated important data needed to plan a larger randomised controlled trial.
While the project was designed primarily to test the feasibility of using intravenous medications, the researchers reported encouraging changes in exploratory outcome measures. Most participants reported reductions in fatigue, improved quality of life, and increased walking distance in a timed walking test, according to the university.
Professor Mark Faghy, Visiting Professor at the University of Derby and Professor of Clinical Exercise Science at Loughborough University, who led the study, said: "These findings are an important step forward in our research into potential treatments for Long Covid. We have shown that it is possible to deliver this intravenous antiviral treatment and undertake the assessments needed to evaluate it in people with Long Covid."
Faghy added: "We also saw encouraging changes in measures including fatigue, functional capacity, quality of life and commonly reported symptoms. While ERASE was not designed to tell us whether the treatment caused those changes or whether the treatment works, the findings give us a strong rationale for carrying out a larger randomised controlled trial that will allow us to answer that question."
More than two million people in the UK are estimated to be living with Long Covid, the university reported. Symptoms can vary considerably and include extreme fatigue, breathlessness, palpitations, and brain fog.
Dr Tom Bewick, the Principal Investigator for University Hospitals of Derby and Burton NHS Foundation Trust on the study, said: "We are proud to participate in the ERASE-Long Covid study in which over 50 long Covid sufferers in Derbyshire were selected to receive a five-day course of antiviral treatment at the Royal Derby Hospital. Following the successful delivery of this pilot, it is the goal to expand this research in the future in a larger randomised trial."
Professor David Strain from the University of Exeter, a clinician and study co-author, said: "We're still seeing large numbers of people who are debilitated by Long Covid in clinic. Our study is a promising step to indicate that the specific antiviral we tested may offer some relief to symptoms, though we now need confirmation in much larger clinical trials to evaluate how effective it is. Our advice to people with long Covid remains to talk to your GP and follow clinical guidance."
Professor Victoria Allgar, Director of the Peninsula Clinical Trials Unit and one of several Plymouth authors on the study, said: "The successful completion of ERASE demonstrates why feasibility studies are so important. Before investing in a large-scale efficacy trial, we need confidence that recruitment, treatment delivery, data collection and participant follow-up can all be achieved. The findings from ERASE show that these key elements are workable in people living with Long Covid and provide the foundations for a future definitive trial."
The research team is now calling for a larger randomised controlled trial to establish whether the antiviral treatment is effective for people with Long Covid. The ERASE trial was conducted five years after the start of the pandemic as part of a wider programme of research led by the University of Derby into the causes and impacts of Long Covid.
For university students, many of whom experienced disrupted studies during the pandemic and some of whom continue to deal with lingering symptoms, this research represents a potential step toward a treatment for a condition that has affected millions. However, the researchers emphasise that the current findings are preliminary and that anyone with Long Covid should follow current clinical guidance and consult their GP.